Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for tough leukemias in early trial

NCT ID NCT06052813

Ongoing Disease control Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an oral drug called BN104 in adults and adolescents with acute leukemia that has come back or not responded to treatment. The drug targets specific genetic changes (KMT2A rearrangement or NPM1 mutation) that drive the cancer. The trial aims to check safety, how the body processes the drug, and whether it can reduce leukemia cells in the bone marrow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BN104 (a menin inhibitor taken orally)

What this could lead to

If successful, this could provide a new treatment option for patients with hard-to-treat acute leukemias that have specific genetic mutations.

What could go wrong

This is an early-phase trial with only 66 participants, so results may not apply broadly. The drug may cause side effects or fail to control the leukemia long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia acute lymphoblastic leukemia acute myeloid leukemia adult acute lymphoblastic leukemia mixed phenotype acute leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKAEMIA ALL, ADULT AML, ADULT KMT2A REARRANGEMENT MENIN INHIBITORS NPM1 MUTATION NUP98 GENE REARRANGEMENT

Contacts and locations

Locations

  • The First Affiliated Hospital of Soochow University

    Suzhou, 215006, China